Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A...
Saved in:
| Published in | Memórias do Instituto Oswaldo Cruz Vol. 111; no. 4; pp. 252 - 257 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Brazil
Fundação Oswaldo Cruz, Fiocruz
01.04.2016
Instituto Oswaldo Cruz, Ministério da Saúde Fundação Oswaldo Cruz (FIOCRUZ) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1678-8060 0074-0276 0074-0276 1678-8060 |
| DOI | 10.1590/0074-02760150390 |
Cover
| Abstract | There are about 350 million hepatitis B virus (HBV) carriers worldwide
and chronic HBV is considered a major public health problem. The
objective of the present study was to assess the effectiveness of the
nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the
treatment of chronic HBV. A cross-sectional study was carried out from
March-December 2013, including all patients with chronic HBV, over 18
years of age, undergoing therapy through the public health system in
southern Brazil. Only the data relating to the first treatments
performed with TDF or ETV were considered. Retreatment, co-infection,
transplanted or immunosuppressed patients were excluded. Six hundred
and forty patients were evaluated, of which 336 (52.5%) received TDF
and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of
nucleos(t)ide analogues and were excluded. The negativation of viral
load was observed in 87.3% and 78.8% and the negativation of hepatitis
B e antigen was achieved in 79% and 72% of those treated with ETV or
TDF, respectively. Negativation of hepatitis B surface antigen was not
observed. There was no occurrence of adverse effects. This is a
real-life study demonstrating that long-term treatment with ETV and TDF
is both safe and effective. |
|---|---|
| AbstractList | There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective.There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective. There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective. There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective. There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the present study was to assess the effectiveness of the nucleos(t)ide analogues tenofovir (TDF) and entecavir (ETV) in the treatment of chronic HBV. A cross-sectional study was carried out from March-December 2013, including all patients with chronic HBV, over 18 years of age, undergoing therapy through the public health system in southern Brazil. Only the data relating to the first treatments performed with TDF or ETV were considered. Retreatment, co-infection, transplanted or immunosuppressed patients were excluded. Six hundred and forty patients were evaluated, of which 336 (52.5%) received TDF and 165 (25.8%) ETV. The other 139 (21.7%) used various combinations of nucleos(t)ide analogues and were excluded. The negativation of viral load was observed in 87.3% and 78.8% and the negativation of hepatitis B e antigen was achieved in 79% and 72% of those treated with ETV or TDF, respectively. Negativation of hepatitis B surface antigen was not observed. There was no occurrence of adverse effects. This is a real-life study demonstrating that long-term treatment with ETV and TDF is both safe and effective. |
| Author | Pereira, Camila V Tovo, Cristiane Valle Mirenda, Henrique Grossmann, Thiago K Almeida, Paulo R.L. de Mattos, Angelo A. de Dal-Pupo, Bruna B |
| AuthorAffiliation | Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Hepatologia, Porto Alegre, RS, Brasil |
| AuthorAffiliation_xml | – name: Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Hepatologia, Porto Alegre, RS, Brasil – name: Universidade Federal de Ciências da Saúde de Porto Alegre |
| Author_xml | – sequence: 1 fullname: Pereira, Camila V – sequence: 2 fullname: Tovo, Cristiane Valle – sequence: 3 fullname: Grossmann, Thiago K – sequence: 4 fullname: Mirenda, Henrique – sequence: 5 fullname: Dal-Pupo, Bruna B – sequence: 6 fullname: Almeida, Paulo R.L. de – sequence: 7 fullname: Mattos, Angelo A. de |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27074254$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1v1DAQjVAR3RbunJCPXLaME9tJLki0KlCpEgfgbNnOpOuV115sp9Ly63G6H6IckCxZnnnvzfjNXFRnPnisqrcUrijv4QNAy5ZQtwIoh6aHF9XiFDqrFlS03bIDAefVRUprKOFGsFfVed0WVM3ZotrdjqM1yuxIGAn6jEY92kiUH0hGH8Ywv6wnZhWDt4ascKuyzTaRazL5ASPJEVXeFOoMyysk20m7J6RyeUXSLmXczLkUppKOnlxH9du619XLUbmEbw73ZfXz8-2Pm6_L-29f7m4-3S81Z5CXNdO9MT1ttAaOwFBwblTdIQetuGlH0YqhbZuu54OGXrRUoOlYrbsauehMc1nd7XWHoNZyG-1GxZ0MysqnQIgPUsVsjUM59MDU2AMdsGe90prjoBjnFJsGodZF62qvlYxFF-Q6TNGX5uX32XY5214DFQDAitm8LoSPe0IxZYODKTZF5Z518Tzj7Uo-hEfJugYoZUXg_UEghl8Tpiw3Nhl0TnkMU5K07ShvBK15gb77u9apyHHYBSD2ABNDShFHaWwu0wxzaeskBTlvlTz95bBVhQj_EI_a_6EcnNI2OOvxxDDRKnkMBlNO8athzR9ggt1o |
| CitedBy_id | crossref_primary_10_1186_s12879_018_3469_y crossref_primary_10_1038_s41598_018_25236_8 crossref_primary_10_14218_JCTH_2020_00164 crossref_primary_10_1111_odi_12692 crossref_primary_10_4236_ojgas_2018_86024 |
| Cites_doi | 10.3748/wjg.v19.i5.721 10.1016/j.jhep.2013.06.007 10.1128/AAC.03845-14 10.1016/j.jhep.2012.04.037 10.1097/MEG.0b013e32835b3677 10.1016/j.jhep.2012.02.010 10.7150/ijms.5472 10.3748/wjg.v20.i23.7169 10.1016/j.jhep.2011.09.018 10.1056/NEJMoa051287 10.1016/S1665-2681(19)30861-0 10.1016/j.jhep.2014.02.013 10.1186/1471-2334-13-181 10.1016/j.jfma.2013.02.001 10.1111/liv.12074 10.1046/j.1423-0410.2001.00003.x 10.1111/j.1440-1746.2012.07269.x 10.1056/NEJMoa0802878 10.1002/hep.510240201 10.1002/hep.24406 10.1097/MEG.0b013e3283511287 10.1056/NEJMoa051285 10.1111/liv.12392 10.1111/jgh.12436 10.1016/S0140-6736(12)61425-1 10.1111/jgh.12108 10.1097/MEG.0000000000000099 10.1002/hep.22841 10.1093/jac/dkr495 10.3748/wjg.v20.i34.12039 10.1111/liv.12057 |
| ContentType | Journal Article |
| Copyright | Copyright - 2016 Memórias do Instituto Oswaldo Cruz This work is licensed under a Creative Commons Attribution 4.0 International License. |
| Copyright_xml | – notice: Copyright - 2016 Memórias do Instituto Oswaldo Cruz – notice: This work is licensed under a Creative Commons Attribution 4.0 International License. |
| DBID | RBI AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM GPN DOA |
| DOI | 10.1590/0074-02760150390 |
| DatabaseName | Bioline International CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) SciELO DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 0074-0276 1678-8060 |
| EndPage | 257 |
| ExternalDocumentID | oai_doaj_org_article_d904af901de949abb5eda4551e33e02b S0074_02762016000400252 PMC4830114 27074254 10_1590_0074_02760150390 cria_bioline_oc_oc16034 |
| Genre | Journal Article |
| GroupedDBID | -~X 123 29M 2WC 5VS 79B ABVJJ ABXHO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS APOWU AZFZN BAWUL BCNDV DIK DU5 E3Z F5P FRP GROUPED_DOAJ GX1 HYE IPNFZ KQ8 M48 OK1 OVT RBI RIG RNS RPM RSC SCD XSB ~02 53G AAYXX CITATION OHT ZGI CGR CUY CVF ECM EIF NPM 7X8 M~E 5PM GPN |
| ID | FETCH-LOGICAL-b540t-24b9cc913bb05e04e655ca28e50ba5c7f676d773895db096716ec842b82e568c3 |
| IEDL.DBID | M48 |
| ISSN | 1678-8060 0074-0276 |
| IngestDate | Wed Aug 27 01:30:44 EDT 2025 Tue Sep 16 21:13:01 EDT 2025 Thu Aug 21 14:04:48 EDT 2025 Thu Sep 04 22:15:00 EDT 2025 Mon Jul 21 05:19:12 EDT 2025 Thu Apr 24 23:05:06 EDT 2025 Tue Jul 01 01:47:37 EDT 2025 Tue Jul 01 18:07:35 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | viral hepatitis hepatitis B virus therapy nucleos(t)ide analogues |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This work is licensed under a Creative Commons Attribution 4.0 International License. http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b540t-24b9cc913bb05e04e655ca28e50ba5c7f676d773895db096716ec842b82e568c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1590/0074-02760150390 |
| PMID | 27074254 |
| PQID | 1781536125 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_d904af901de949abb5eda4551e33e02b scielo_journals_S0074_02762016000400252 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4830114 proquest_miscellaneous_1781536125 pubmed_primary_27074254 crossref_citationtrail_10_1590_0074_02760150390 crossref_primary_10_1590_0074_02760150390 bioline_primary_cria_bioline_oc_oc16034 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-04-01 |
| PublicationDateYYYYMMDD | 2016-04-01 |
| PublicationDate_xml | – month: 04 year: 2016 text: 2016-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Brazil |
| PublicationPlace_xml | – name: Brazil |
| PublicationTitle | Memórias do Instituto Oswaldo Cruz |
| PublicationTitleAlternate | Mem Inst Oswaldo Cruz |
| PublicationYear | 2016 |
| Publisher | Fundação Oswaldo Cruz, Fiocruz Instituto Oswaldo Cruz, Ministério da Saúde Fundação Oswaldo Cruz (FIOCRUZ) |
| Publisher_xml | – name: Fundação Oswaldo Cruz, Fiocruz – name: Instituto Oswaldo Cruz, Ministério da Saúde – name: Fundação Oswaldo Cruz (FIOCRUZ) |
| References | Chang TT (ref4) 2006; 354 Lee YB (ref11) 2014; 58 Lin C (ref14) 2013; 112 Liaw YF (ref12) 2013; 33 Yu SJ (ref35) 2014; 20 Ridruejo E (ref25) 2014; 20 Wang CC (ref34) 2013; 28 Ridruejo E (ref26) 2014; 13 Tenney DJ (ref30) 2009; 49 Ono A (ref21) 2012; 57 Marcellin P (ref17) 2013; 381 Petersen J (ref24) 2012; 56 (ref20) 2010 Saldanha J (ref27) 2001; 80 Pan CQ (ref23) 2014; 9 Seto W (ref28) 2013; 59 Luo J (ref16) 2013; 10 Chen C (ref5) 2014; 60 Buti M (ref2) 2014; 34 Lin B (ref13) 2013; 28 Lai CL (ref10) 2006; 354 Marcellin P (ref18) 2008; 359 Bedossa P (ref1) 1996; 24 Fahrtash-Bahin F (ref7) 2013; 19 Ozaras R (ref22) 2014; 26 Liu A (ref15) 2013; 25 (ref19) 2009 Buti M (ref3) 2012; 24 Zoutendijk R (ref36) 2011; 54 Hahné SJ (ref8) 2013; 13 Ke W (ref9) 2014; 9 Tsai M (ref31) 2014; 29 (ref6) 2012; 57 Souto FJD (ref29) 1999; 18 Van Bommel F (ref33) 2013; 33 Tsai MC (ref32) 2012; 67 22989322 - J Gastroenterol Hepatol. 2013 Jan;28(1):46-50 24756007 - Ann Hepatol. 2014 May-Jun;13(3):327-36 23234725 - Lancet. 2013 Feb 9;381(9865):468-75 16525137 - N Engl J Med. 2006 Mar 9;354(10):1001-10 8690394 - Hepatology. 1996 Aug;24(2):289-93 24583247 - J Hepatol. 2014 Jun;60(6):1127-34 22382708 - Eur J Gastroenterol Hepatol. 2012 May;24(5):535-42 23286854 - Liver Int. 2013 Feb;33 Suppl 1:111-5 16525138 - N Engl J Med. 2006 Mar 9;354(10):1011-20 23169311 - Eur J Gastroenterol Hepatol. 2013 Mar;25(3):338-43 23430314 - World J Gastroenterol. 2013 Feb 7;19(5):721-6 19052126 - N Engl J Med. 2008 Dec 4;359(23):2442-55 23787007 - J Formos Med Assoc. 2013 Jun;112(6):302-11 25155601 - Antimicrob Agents Chemother. 2014 Nov;58(11):6710-6 23286862 - Liver Int. 2013 Feb;33 Suppl 1:176-81 23471472 - Int J Med Sci. 2013;10(4):427-33 22174039 - J Antimicrob Chemother. 2012 Mar;67(3):696-9 25232241 - World J Gastroenterol. 2014 Sep 14;20(34):12039-44 22659518 - J Hepatol. 2012 Sep;57(3):508-14 24901822 - Eur J Gastroenterol Hepatol. 2014 Jul;26(7):774-80 23597411 - BMC Infect Dis. 2013;13:181 24905092 - PLoS One. 2014;9(6):e98865 21563196 - Hepatology. 2011 Aug;54(2):443-51 24716215 - J Gastroenterol Hepatol. 2014 Mar;29(3):568-75 22436845 - J Hepatol. 2012 Jul;57(1):167-85 19280622 - Hepatology. 2009 May;49(5):1503-14 23792029 - J Hepatol. 2013 Oct;59(4):709-16 11339072 - Vox Sang. 2001 Jan;80(1):63-71 24966587 - World J Gastroenterol. 2014 Jun 21;20(23):7169-80 24373086 - Liver Int. 2014 Feb;34 Suppl 1:108-11 24594870 - PLoS One. 2014;9(3):e89789 23278507 - J Gastroenterol Hepatol. 2013 May;28(5):855-60 22037226 - J Hepatol. 2012 Mar;56(3):520-6 2013; 25 2013; 28 2010 2009 2014; 26 2011; 54 2014; 29 2012; 57 2013; 381 2012; 56 2014; 60 2006; 354 2009; 49 2014; 20 2013; 19 2001; 80 2013; 59 2013; 33 2013; 10 2013; 13 1999; 18 2013; 112 2014; 58 2008; 359 2014; 13 2014; 9 1996; 24 2012; 24 2012; 67 2014; 34 |
| References_xml | – volume: 19 start-page: 721 year: 2013 ident: ref7 article-title: Australian tertiary care outcomes of entecavir monotherapy in treatment-naïve patients with chronic hepatitis B publication-title: World J Gastroenterol doi: 10.3748/wjg.v19.i5.721 – volume: 59 start-page: 709 year: 2013 ident: ref28 article-title: Pattern of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment publication-title: J Hepatol doi: 10.1016/j.jhep.2013.06.007 – volume: 58 start-page: 6710 year: 2014 ident: ref11 article-title: Efficacy of entecavir plus tnofovir combination therapy for chronic hepatitis B patients with multi-drug resistant strains publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.03845-14 – volume: 57 start-page: 508 year: 2012 ident: ref21 article-title: Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients publication-title: J Hepatol doi: 10.1016/j.jhep.2012.04.037 – volume: 25 start-page: 338 year: 2013 ident: ref15 article-title: Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e32835b3677 – volume: 57 start-page: 167 year: 2012 ident: ref6 article-title: EASL clinical practice guidelines: management of chronic hepatitis B virus infection publication-title: J Hepatol doi: 10.1016/j.jhep.2012.02.010 – volume: 10 start-page: 427 year: 2013 ident: ref16 article-title: Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life publication-title: Int J Med Sci doi: 10.7150/ijms.5472 – volume: 20 start-page: 7169 year: 2014 ident: ref25 article-title: Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i23.7169 – volume: 56 start-page: 520 year: 2012 ident: ref24 article-title: Entecavir plus Tenofovir combination as rescue therapy in pre-treated chronic B patients: an international multicenter cohort study publication-title: J Hepatol doi: 10.1016/j.jhep.2011.09.018 – volume: 354 start-page: 1011 year: 2006 ident: ref10 article-title: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B publication-title: N Engl J Med doi: 10.1056/NEJMoa051287 – year: 2009 ident: ref19 – volume: 13 start-page: 327 year: 2014 ident: ref26 article-title: Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice publication-title: Ann Hepatol doi: 10.1016/S1665-2681(19)30861-0 – volume: 60 start-page: 1127 year: 2014 ident: ref5 article-title: Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation publication-title: J Hepatol doi: 10.1016/j.jhep.2014.02.013 – year: 2010 ident: ref20 – volume: 13 year: 2013 ident: ref8 article-title: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening publication-title: BMC Infect Dis doi: 10.1186/1471-2334-13-181 – volume: 112 start-page: 302 year: 2013 ident: ref14 article-title: Hepatitis B viral factors and treatment responses in chronic hepatitis B publication-title: J Formos Med Assoc doi: 10.1016/j.jfma.2013.02.001 – volume: 33 start-page: 176 year: 2013 ident: ref33 article-title: Treatment of HBV related cirrhosis publication-title: Liver Int doi: 10.1111/liv.12074 – volume: 80 start-page: 63 year: 2001 ident: ref27 article-title: An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques publication-title: Vox Sang doi: 10.1046/j.1423-0410.2001.00003.x – volume: 28 start-page: 46 year: 2013 ident: ref34 article-title: Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2012.07269.x – volume: 359 start-page: 2442 year: 2008 ident: ref18 article-title: Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B publication-title: N Engl J Med doi: 10.1056/NEJMoa0802878 – volume: 9 year: 2014 ident: ref9 article-title: Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection - a systematic review and meta-analysis publication-title: PLoS ONE – volume: 24 start-page: 289 year: 1996 ident: ref1 article-title: An algorithm for the grading of activity in chronic hepatitis C publication-title: Hepatology doi: 10.1002/hep.510240201 – volume: 54 start-page: 443 year: 2011 ident: ref36 article-title: Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response publication-title: Hepatology doi: 10.1002/hep.24406 – volume: 24 start-page: 535 year: 2012 ident: ref3 article-title: Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0b013e3283511287 – volume: 354 start-page: 1001 year: 2006 ident: ref4 article-title: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B publication-title: N Engl J Med doi: 10.1056/NEJMoa051285 – volume: 34 start-page: S108 year: 2014 ident: ref2 article-title: HBeAg-positive chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogs? publication-title: Liver Int doi: 10.1111/liv.12392 – volume: 29 start-page: 568 year: 2014 ident: ref31 article-title: Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12436 – volume: 381 start-page: 468 year: 2013 ident: ref17 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study publication-title: Lancet doi: 10.1016/S0140-6736(12)61425-1 – volume: 9 year: 2014 ident: ref23 article-title: Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings publication-title: PLoS ONE – volume: 28 start-page: 855 year: 2013 ident: ref13 article-title: Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice publication-title: J Gastroenterol Hepatol doi: 10.1111/jgh.12108 – volume: 26 year: 2014 ident: ref22 article-title: First-line monotherapy of tenofovir or entecavir have comparable efficacies in hepatitis B treatment publication-title: Eur J Gastroenterol Hepatol doi: 10.1097/MEG.0000000000000099 – volume: 18 start-page: 143 year: 1999 ident: ref29 article-title: Distribuição da hepatite B no Brasil: atualização do mapa epidemiológico e proposições para seu controle publication-title: Gastroenterol Endosc Digest – volume: 49 start-page: 1503 year: 2009 ident: ref30 article-title: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy publication-title: Hepatology doi: 10.1002/hep.22841 – volume: 67 start-page: 696 year: 2012 ident: ref32 article-title: A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr495 – volume: 20 start-page: 12039 year: 2014 ident: ref35 article-title: Hepatitis B viral load affects prognosis of hepatocellular carcinoma publication-title: World J Gastroenterol doi: 10.3748/wjg.v20.i34.12039 – volume: 33 start-page: 111 year: 2013 ident: ref12 article-title: Impact of therapy on the outcome of chronic hepatitis B publication-title: Liver Int doi: 10.1111/liv.12057 – reference: 25232241 - World J Gastroenterol. 2014 Sep 14;20(34):12039-44 – reference: 21563196 - Hepatology. 2011 Aug;54(2):443-51 – reference: 24373086 - Liver Int. 2014 Feb;34 Suppl 1:108-11 – reference: 24594870 - PLoS One. 2014;9(3):e89789 – reference: 8690394 - Hepatology. 1996 Aug;24(2):289-93 – reference: 24905092 - PLoS One. 2014;9(6):e98865 – reference: 23471472 - Int J Med Sci. 2013;10(4):427-33 – reference: 16525138 - N Engl J Med. 2006 Mar 9;354(10):1011-20 – reference: 23792029 - J Hepatol. 2013 Oct;59(4):709-16 – reference: 23278507 - J Gastroenterol Hepatol. 2013 May;28(5):855-60 – reference: 24716215 - J Gastroenterol Hepatol. 2014 Mar;29(3):568-75 – reference: 22037226 - J Hepatol. 2012 Mar;56(3):520-6 – reference: 22382708 - Eur J Gastroenterol Hepatol. 2012 May;24(5):535-42 – reference: 24583247 - J Hepatol. 2014 Jun;60(6):1127-34 – reference: 24901822 - Eur J Gastroenterol Hepatol. 2014 Jul;26(7):774-80 – reference: 24756007 - Ann Hepatol. 2014 May-Jun;13(3):327-36 – reference: 19280622 - Hepatology. 2009 May;49(5):1503-14 – reference: 22989322 - J Gastroenterol Hepatol. 2013 Jan;28(1):46-50 – reference: 25155601 - Antimicrob Agents Chemother. 2014 Nov;58(11):6710-6 – reference: 23286854 - Liver Int. 2013 Feb;33 Suppl 1:111-5 – reference: 23597411 - BMC Infect Dis. 2013;13:181 – reference: 22659518 - J Hepatol. 2012 Sep;57(3):508-14 – reference: 23286862 - Liver Int. 2013 Feb;33 Suppl 1:176-81 – reference: 23430314 - World J Gastroenterol. 2013 Feb 7;19(5):721-6 – reference: 11339072 - Vox Sang. 2001 Jan;80(1):63-71 – reference: 16525137 - N Engl J Med. 2006 Mar 9;354(10):1001-10 – reference: 24966587 - World J Gastroenterol. 2014 Jun 21;20(23):7169-80 – reference: 22436845 - J Hepatol. 2012 Jul;57(1):167-85 – reference: 23234725 - Lancet. 2013 Feb 9;381(9865):468-75 – reference: 23787007 - J Formos Med Assoc. 2013 Jun;112(6):302-11 – reference: 19052126 - N Engl J Med. 2008 Dec 4;359(23):2442-55 – reference: 23169311 - Eur J Gastroenterol Hepatol. 2013 Mar;25(3):338-43 – reference: 22174039 - J Antimicrob Chemother. 2012 Mar;67(3):696-9 – volume: 19 start-page: 721 year: 2013 end-page: 726 article-title: Australian tertiary care outcomes of entecavir monotherapy in treatment-naïve patients with chronic hepatitis B publication-title: World J Gastroenterol – volume: 54 start-page: 443 year: 2011 end-page: 451 article-title: Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response publication-title: Hepatology – volume: 20 start-page: 12039 year: 2014 end-page: 12044 article-title: Hepatitis B viral load affects prognosis of hepatocellular carcinoma publication-title: World J Gastroenterol – volume: 28 start-page: 855 year: 2013 end-page: 860 article-title: Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice publication-title: J Gastroenterol Hepatol – volume: 10 start-page: 427 year: 2013 end-page: 433 article-title: Efficacy of entecavir treatment for up to 5 years in nucleos(t)ide-naïve chronic hepatitis B patients in real life publication-title: Int J Med Sci – volume: 381 start-page: 468 year: 2013 end-page: 475 article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study publication-title: Lancet – volume: 34 start-page: S108 year: 2014 end-page: S111 article-title: HBeAg-positive chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogs? publication-title: Liver Int – volume: 24 start-page: 535 year: 2012 end-page: 542 article-title: Efficacy and safety of entecavir in clinical practice in treatment-naïve Caucasian chronic hepatitis B patients publication-title: Eur J Gastroenterol Hepatol – volume: 359 start-page: 2442 year: 2008 end-page: 2455 article-title: Tenofovir disoproxilfumarate versus adefovir dipivoxil for chronic hepatitis B publication-title: N Engl J Med – volume: 25 start-page: 338 year: 2013 end-page: 343 article-title: Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice publication-title: Eur J Gastroenterol Hepatol – volume: 29 start-page: 568 year: 2014 end-page: 575 article-title: Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus-related compensated cirrhosis publication-title: J Gastroenterol Hepatol – volume: 57 start-page: 508 year: 2012 end-page: 514 article-title: Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients publication-title: J Hepatol – volume: 56 start-page: 520 year: 2012 end-page: 526 article-title: Entecavir plus Tenofovir combination as rescue therapy in pre-treated chronic B patients: an international multicenter cohort study publication-title: J Hepatol – volume: 59 start-page: 709 year: 2013 end-page: 716 article-title: Pattern of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment publication-title: J Hepatol – volume: 18 start-page: 143 year: 1999 end-page: 150 article-title: Distribuição da hepatite B no Brasil: atualização do mapa epidemiológico e proposições para seu controle publication-title: Gastroenterol Endosc Digest – volume: 33 start-page: 176 year: 2013 end-page: 181 article-title: Treatment of HBV related cirrhosis publication-title: Liver Int – volume: 354 start-page: 1001 year: 2006 end-page: 1010 article-title: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B publication-title: N Engl J Med – volume: 57 start-page: 167 year: 2012 end-page: 185 article-title: EASL clinical practice guidelines: management of chronic hepatitis B virus infection publication-title: J Hepatol – volume: 112 start-page: 302 year: 2013 end-page: 311 article-title: Hepatitis B viral factors and treatment responses in chronic hepatitis B publication-title: J Formos Med Assoc – year: 2010 publication-title: Estudo de prevalência de base populacional das infecções pelo vírus das hepatites A, B e C nas capitais do Brasil (2010) – volume: 58 start-page: 6710 year: 2014 end-page: 6716 article-title: Efficacy of entecavir plus tnofovir combination therapy for chronic hepatitis B patients with multi-drug resistant strains publication-title: Antimicrob Agents Chemother – volume: 9 year: 2014 article-title: Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection - a systematic review and meta-analysis publication-title: PLoS ONE – volume: 80 start-page: 63 year: 2001 end-page: 71 article-title: An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques publication-title: Vox Sang – year: 2009 publication-title: Portaria n. 2.561. Protocolo clínico e diretrizes terapêuticas - hepatite viral crônica B e coinfecções – volume: 354 start-page: 1011 year: 2006 end-page: 1020 article-title: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B publication-title: N Engl J Med – volume: 33 start-page: 111 year: 2013 end-page: 115 article-title: Impact of therapy on the outcome of chronic hepatitis B publication-title: Liver Int – volume: 28 start-page: 46 year: 2013 end-page: 50 article-title: Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir publication-title: J Gastroenterol Hepatol – volume: 13 year: 2013 article-title: Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening publication-title: BMC Infect Dis – volume: 60 start-page: 1127 year: 2014 end-page: 1134 article-title: Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation publication-title: J Hepatol – volume: 49 start-page: 1503 year: 2009 end-page: 1514 article-title: Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy publication-title: Hepatology – volume: 13 start-page: 327 year: 2014 end-page: 336 article-title: Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice publication-title: Ann Hepatol – volume: 24 start-page: 289 year: 1996 end-page: 293 article-title: An algorithm for the grading of activity in chronic hepatitis C publication-title: Hepatology – volume: 26 year: 2014 article-title: First-line monotherapy of tenofovir or entecavir have comparable efficacies in hepatitis B treatment publication-title: Eur J Gastroenterol Hepatol – volume: 9 year: 2014 article-title: Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings publication-title: PLoS ONE – volume: 67 start-page: 696 year: 2012 end-page: 699 article-title: A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice publication-title: J Antimicrob Chemother – volume: 20 start-page: 7169 year: 2014 end-page: 7180 article-title: Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir publication-title: World J Gastroenterol |
| SSID | ssj0027364 |
| Score | 2.1408472 |
| Snippet | There are about 350 million hepatitis B virus (HBV) carriers worldwide
and chronic HBV is considered a major public health problem. The
objective of the... There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the... There are about 350 million hepatitis B virus (HBV) carriers worldwide and chronic HBV is considered a major public health problem. The objective of the... |
| SourceID | doaj scielo pubmedcentral proquest pubmed crossref bioline |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 252 |
| SubjectTerms | Antiviral Agents - therapeutic use Cross-Sectional Studies DNA, Viral Female Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis B e Antigens - immunology Hepatitis B Surface Antigens - immunology hepatitis B virus Hepatitis B virus - immunology Hepatitis B, Chronic - drug therapy Humans Male Middle Aged nucleos(t)ide analogues PARASITOLOGY Public Health Tenofovir - therapeutic use therapy Treatment Outcome TROPICAL MEDICINE viral hepatitis Viral Load |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYltKWX0vTptgkqFEoPZmVZsuRjtySEQnppA7kJvUwMi112N4Xk12fGss0ubekl4Isl-SHNeOYba_SJkI8hNMJqJ_IKfEMupG9y67XLeVQ2Fk7IMuIC5_Pv1dmF-HYpL3e2-sKcsEQPnAZuEWombANeK8Ra1NY5GYMV4OdjWUbGHVpfVrMpmJpCrXIgjirAFIMNrtg4QSlrtkCniTOXFcb6JdriR8h3BJhuzzUNDP5_g51_Zk8-RGe12vVLp8_I0xFQ0i-pI4fkQeyek8fn45T5C3JzgiQR1t_QvqFIwOnt73ZNbRcowOW-6fGs7ahPLLn0KmKO9bbd0CXFBWZrOueiYzPAizRRY9O0hJImLmis2_RDunxHl2t7265ekovTk59fz_Jxv4XcAW7b5ly42vu6KJ1jMjIRKym95TpK5qz0qqlUFZQCiCODg9AHQq3oteBO8ygr7ctX5KDru_iG0EJwxgOyhTVKeCdqVwoIlYJrXKl1YzPyaRx08yuxahgwktZMhb2HA3fAFhlZTEIxfqQtx90zVgbDFxCoQYGaHYFm5PN8xXTzf7ddopzndki2PRSACppRBc3_VDAjHyYtMfBx4oyL7WJ_vTGF0uBREERm5HXSmvlRXOFvCQkdVHv6tPcu-zVdezUQgAs9xLEwiEnzzGh3NubH3EGO1IGDieaSv72Pbr4jT_CmKW3pPTnYrq_jESCyrTsePr47wwswpw priority: 102 providerName: Directory of Open Access Journals |
| Title | Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil |
| URI | http://www.bioline.org.br/abstract?id=oc16034 https://www.ncbi.nlm.nih.gov/pubmed/27074254 https://www.proquest.com/docview/1781536125 https://pubmed.ncbi.nlm.nih.gov/PMC4830114 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762016000400252&lng=en&tlng=en https://doaj.org/article/d904af901de949abb5eda4551e33e02b |
| Volume | 111 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA66ivgi63XrZYkgiA_VNk3a9EFkR3ZdhPVFB-Yt5Fa3MLRrZ1Ycf73npJfdwRGEoTBtess5yfm-5uQLIa-cq7iWhsc5xIaYC1vF2koTM19onxouMo8TnM--5Kdz_nkhFlfTo4cKXO2kdrie1Lxbvv31Y_MBGvz7sHpPCawecwqBXuXI3oHD3yS3wmgRJvJxeUW_siAmlUL3DP1yngyDlruuAGAYNZAA522Fq6DqvwuK_p1ReRsD2PJ6rDrZJ_cGkEmPeq-4T2745gG5czYMoz8km2MUjtB2Q9uKoiin1T_rjurGUYDQbdXiv7qhtlfOpece867X9YrOKE466-iUn47FAEPSXi6b9tMqaa8PjcdWbUihb-is07_r5SMyPzn-9vE0HtZgiA1guXXMuCmtLdPMmET4hPtcCKuZ9CIxWtiiyovcFQXAHuEM0CGgX95KzoxkXuTSZo_JXtM2_oDQlLOEOVQQqwpuDS9NxoE-OVOZTMpKR-T1UOnqolfaUNBxajXubC38cFVsHpF3o1GUHaTMcUWNpUJKAwZVaFB1zaAReTOdMV7832VnaOepHApwhx1t910N7Vm5MuG6AjDlfMlLbYzwTnOAnz7LfMJMRF6OXqKgweIojG58e7lSaSEhyiCwjMiT3mumW7ECP1UIeMFiy5-2nmX7SFOfB1FwLgO3hUrsPU-NTUl9nV6QoZxg6LaZYE__u7qfkbt4Zp-v9JzsrbtL_wKg2Nochk8YsP20SA9Da_sDP_kxBA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+entecavir+and+tenofovir+in+chronic+hepatitis+B+under+treatment+in+the+public+health+system+in+southern+Brazil&rft.jtitle=Mem%C3%B3rias+do+Instituto+Oswaldo+Cruz&rft.au=Pereira%2C+Camila+V&rft.au=Tovo%2C+Cristiane+Valle&rft.au=Grossmann%2C+Thiago+K&rft.au=Mirenda%2C+Henrique&rft.date=2016-04-01&rft.pub=Funda%C3%A7%C3%A3o+Oswaldo+Cruz%2C+Fiocruz&rft.issn=1678-8060&rft.volume=111&rft.issue=4&rft_id=info:doi/10.1590%2F0074-02760150390&rft.externalDBID=n%2Fa&rft.externalDocID=cria_bioline_oc_oc16034 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1678-8060&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1678-8060&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1678-8060&client=summon |